% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ceccon:844796,
      author       = {Ceccon, Garry and Lazaridis, Lazaros and Stoffels, Gabriele
                      and Rapp, Marion and Weber, Manuel and Blau, Tobias and
                      Lohmann, Phillip and Kebir, Sied and Herrmann, Ken and Fink,
                      Gereon R. and Langen, Karl-Josef and Glas, Martin and
                      Galldiks, Norbert},
      title        = {{U}se of {FET} {PET} in glioblastoma patients undergoing
                      neurooncological treatment including tumour-treating fields:
                      initial experience},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {45},
      number       = {9},
      issn         = {1619-7089},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {FZJ-2018-02172},
      pages        = {1626 - 1635},
      year         = {2018},
      abstract     = {PurposeWe present our first clinical experience with
                      O-(2-18F-fluoroethyl)-l-tyrosine (FET) PET in patients with
                      high-grade glioma treated with various neurooncological
                      therapies including tumour-treating fields (TTFields) for
                      the differentiation of tumour progression from
                      treatment-related changes.MethodsWe retrospectively assessed
                      12 patients (mean age 51 ± 12 years, range 33–72
                      years) with high-grade glioma (11 glioblastomas, 1
                      gliosarcoma) in whom the treatment regimen included TTFields
                      and who had undergone FET PET scans for differentiation of
                      tumour progression from treatment-related changes. Mean and
                      maximum tumour-to-brain ratios (TBRmean, TBRmax) were
                      calculated. The definitive diagnosis (tumour progression or
                      posttherapeutic changes) was confirmed either by
                      histopathology (4 of 12 patients) or on clinical
                      follow-up.ResultsIn all nine patients with confirmed tumour
                      progression, the corresponding FET PET showed increased
                      uptake (TBRmax 3.5 ± 0.6, TBRmean 2.7 ± 0.7). In
                      one of these nine patients, FET PET was consistent with
                      treatment-related changes, whereas standard MRI showed a
                      newly diagnosed contrast-enhancing lesion. In two patients
                      treated solely with TTFields without any other concurrent
                      neurooncological therapy, serial FET PET revealed a decrease
                      in metabolic activity over a follow-up of 6 months or no FET
                      uptake without any signs of tumour progression or residual
                      tumour on conventional MRI.ConclusionFET PET may add
                      valuable information in monitoring therapy in individual
                      patients with high-grade glioma undergoing neurooncological
                      treatment including TTFields.},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29564490},
      UT           = {WOS:000437733300016},
      doi          = {10.1007/s00259-018-3992-5},
      url          = {https://juser.fz-juelich.de/record/844796},
}